Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
Open Access
- 12 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Precision Oncology
- Vol. 5 (1), 1-6
- https://doi.org/10.1038/s41698-021-00145-8
Abstract
The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy. Treatment with chemoradiation approaches has not significantly improved patient outcomes. Similarly, trials of therapies targeting MPNST genomic drivers have thus far been unsuccessful. Improved understanding of the molecular pathogenesis of MPNST indicates frequent activation of the mitogen-activated protein kinase (MAPK) cell signaling pathway. MEK inhibitors have shown activity in preclinical studies; however, their clinical efficacy has not been reported to date. We describe here a case of sustained complete response to MEK inhibition in an adolescent patient with a recurrent metastatic MPNST with multiple alterations in the MAPK pathway, guided by a precision oncology approach.Keywords
This publication has 44 references indexed in Scilit:
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsJCI Insight, 2012
- Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1Neuro-Oncology, 2012
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical ModelJournal of Clinical Oncology, 2009
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent SarcomasJournal of Clinical Oncology, 2009
- EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapyNeuro-Oncology, 2008
- Malignant peripheral nerve sheath tumor of the breast: case reportWorld Journal of Surgical Oncology, 2007
- Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1Journal of Medical Genetics, 2007
- Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative GroupJournal of Clinical Oncology, 2005
- SUZ12 Is Required for Both the Histone Methyltransferase Activity and the Silencing Function of the EED-EZH2 ComplexMolecular Cell, 2004
- Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase PathwayOnline Journal of Public Health Informatics, 2001